Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
25.26
+1.30 (5.43%)
At close: May 12, 2025, 4:00 PM
25.17
-0.09 (-0.36%)
After-hours: May 12, 2025, 5:58 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Summit Therapeutics stock have an average target of 37, with a low estimate of 30 and a high estimate of 44. The average target predicts an increase of 46.48% from the current stock price of 25.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Summit Therapeutics stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 6 | 7 | 7 |
| Buy | 2 | 2 | 2 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $37 → $41 | Strong Buy | Maintains | $37 → $41 | +62.31% | May 2, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $40 | Buy | Reiterates | $40 | +58.35% | Apr 28, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $31 → $44 | Strong Buy | Maintains | $31 → $44 | +74.19% | Apr 25, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 23, 2025 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $23 → $35 | Hold → Strong Buy | Upgrades | $23 → $35 | +38.56% | Mar 26, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
53.05M
EPS This Year
-0.42
from -0.31
EPS Next Year
-0.58
from -0.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 174.1M | 449.4M | ||
| Avg | n/a | 53.1M | 136.6M | ||
| Low | n/a | n/a | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 747.1% | ||
| Avg | - | - | 157.4% | ||
| Low | - | - | -81.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.41 | -0.47 | -0.29 | ||
| Avg | -0.42 | -0.58 | -0.58 | ||
| Low | -0.46 | -0.70 | -0.86 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.